New genetic treatments for rare diseases using advanced viral vectors
Official title: Development of novel genetic medicine approaches to treat orphan diseases
Funded at Kinea Bio, INC. · NIH-11324445 · Data updated 2026-11-12
This study is exploring new ways to use genetic medicine to help people with rare muscle diseases caused by gene mutations, aiming to deliver complete genes more effectively to improve treatment options for those affected.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Kinea Bio, INC. NIH-funded |
| Lab location | 1 site (Mukilteo, UNITED STATES) |
| Project start | September 19, 2024 |
| Project end | May 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $1,159,305 |
| NIH project number | 4R44AR083801-02 |
| Project ID | NIH-11324445 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with dysferlinopathies or other muscular dystrophies caused by large gene mutations.
✕Less likely to help
Patients with genetic disorders that do not involve large gene mutations or those not affected by muscular dystrophies may not benefit from this research.
What this research studies
This research focuses on developing innovative genetic medicine approaches to treat orphan diseases, particularly those caused by mutations in large genes like dysferlin. The team aims to utilize adeno-associated viral (AAV) vectors to deliver full-length genes effectively, overcoming the limitations of traditional AAV delivery methods. By employing a dual vector strategy, they plan to enhance the expression of therapeutic proteins in patients with muscular dystrophies. This approach could potentially provide a more effective treatment option for individuals suffering from these rare genetic disorders.
Why it matters
Potential benefit: If successful, this research could lead to effective treatments for patients with rare genetic disorders, improving their quality of life.
How similar studies have gone: Previous research has shown promise in using dual AAV vectors for gene therapy, indicating potential success for this novel approach.
Where this research is happening
-
Kinea Bio, INC.
Mukilteo, United States Active
Researchers
- Principal investigator: Childers, Martin K — Kinea Bio, INC.
- Study coordinator: Childers, Martin K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.